Gordon Research Conferences
Meeting Details
Search:
  GO

New Antibacterial Discovery and Development
Gordon Research Conference

Enabling the Next Generation of Antibacterial Drugs

Dates

March 13-18, 2016

Location

Renaissance Tuscany Il Ciocco
Lucca (Barga), Italy

Organizers

Chairs:
Heike Broetz-Oesterhelt & Jennifer A. Leeds

Vice Chairs:
Richard E. Lee & Terry Roemer

Meeting Description

This Gordon Research Conference and its companion Gordon Research Seminar will bring highly experienced leaders in antibacterial drug discovery and development together with young investigators and those new to the field of antibiotics research in order to enable the next generation of safe and effective drugs. Discussion leaders and speakers are chosen from academia, industry, and government agencies to emphasize the breadth of talent and leadership necessary to drive innovation around target discovery and validation, hit identification and chemical optimization, and clinical trial design and execution. Previous meetings have defined the problem of antibiotic resistance, the challenges in antibiotic discovery and development faced over the past two decades, and the need for new pathways for clinical development. Those meetings have successfully created a community of idea generation and collaboration in what is otherwise a highly competitive scientific arena. This meeting will build on those foundations by exploring 1) novel strategies for achieving potent and safe antibacterial drugs against the most difficult-to-treat organisms, 2) new approaches for diagnosing infections with the goal of broadening the opportunities for clinical development as well as guiding the appropriate use of precious new antibacterial drugs in the clinic, and 3) learnings from recent clinical programs with new and established targets which may be translatable to the next generation of antibacterial drugs.

Many strategic and organizational changes have taken place in the biotech and pharmaceutical industry over the last few years as well as a shift in emphasis at academic and government research facilities from early basic science to translational research. Because of the ever-changing environment, there has never been a more critical time for fostering a community of intellectuals dedicated to innovation and calculated risk-taking. This GRC (and associated GRS) will enable critical thinking, robust discussions around data gathering and interpretation, and learning from each others' challenges and successes. Most importantly the GRC/GRS meetings will provide a community and support network for scientists who have dedicated their careers to one of the most difficult and essential areas of human medicine.

Related Meeting

This GRC was held in conjunction with the "New Antibacterial Discovery and Development" Gordon Research Seminar (GRS). Refer to the associated GRS program page for more information.

Contributors

Final Meeting Program

Sunday
4:00 pm - 8:00 pmArrival and Check-in
6:00 pmDinner
7:30 pm - 7:40 pmWelcome / Introductory Comments by GRC Site Staff
7:40 pm - 9:30 pmKeynote Session: The Role of Government in Enabling New Antibacterial Discovery and Development
Discussion Leaders: Heike Broetz-Oesterhelt (Institute for Microbiology and Infection Medicine, University of Tübingen, Germany) and Jennifer Leeds (Novartis Institutes for BioMedical Research, USA)
7:40 pm - 7:55 pmOpening Remarks
7:55 pm - 8:00 pmIntroduction by Discussion Leader
8:00 pm - 8:35 pmSally Davies (U.K. Department of Health, United Kingdom)
"Global Policy in Antimicrobial Resistance (AMR)"
8:35 pm - 8:45 pmDiscussion
8:45 pm - 9:20 pmSumathi Nambiar (U.S. Food and Drug Administration, USA)
"FDA Perspective on Antibacterial Drug Development"
9:20 pm - 9:30 pmDiscussion
Monday
7:30 am - 8:30 amBreakfast
9:00 am - 12:30 pmNew Antibacterial Targets: Focusing on Likelihood of Success
This session will focus on which new targets deserve our attention, and why are they more likely to enable successful drugs.
Discussion Leader: Hans-Georg Sahl (University of Bonn, Germany)
9:00 am - 9:05 amIntroduction by Discussion Leader
9:05 am - 9:40 amSarah McLeod (Entasis Therapeutics, USA)
"Small Molecule Inhibitors of Gram-Negative Lipoprotein Trafficking Discovered by Phenotypic Screening"
9:40 am - 9:50 amDiscussion
9:50 am - 10:25 amTanja Schneider (University of Bonn, Germany)
"Targeting Bactoprenol-Bound Cell Envelope Precursors"
10:25 am - 10:35 amDiscussion
10:35 am - 11:00 amCoffee Break
11:00 am - 11:35 amSarah Ades (Pennsylvania State University, USA)
"Targeting Stress: Identifying Inhibitors of SigmaE-Hfq-sRNA Virulence Pathway"
11:35 am - 11:45 amDiscussion
11:45 am - 12:20 pmRolf Mueller (Helmholtz-Institute for Pharmaceutical Research Saarland, Germany)
"Natural Product Research Towards Innovative Antibacterial Target-Compound Pairs: Challenges and Opportunities"
12:20 pm - 12:30 pmDiscussion
12:30 pmLunch
1:30 pm - 4:30 pmFree Time
3:00 pm - 4:00 pmPower Hour
The GRC Power Hour is an optional informal gathering open to all meeting participants. It is designed to help address the challenges women face in science and support the professional growth of women in our communities by providing an open forum for discussion and mentoring.
Organizers: Aileen Rubio (Spero Therapeutics, USA) and Nienke Buddelmeijer (Institut Pasteur, France)
4:30 pm - 6:00 pmPoster Session
6:00 pm - 8:00 pmTechnologies to Enable Antibacterial Discovery and Development
This session will focus on what technologies are necessary to bring new compounds against novel targets to the clinic, and where are the innovative approaches to doing so.
Discussion Leader: Terry Roemer (Merck Infectious Disease Research, USA)
6:00 pm - 6:05 pmIntroduction by Discussion Leader
6:05 pm - 6:30 pmDomingo Gargallo-Viola (ABAC Therapeutics, Spain)
"Use of the PasNas Platform to Enable High Quality Antibacterial Hit Finding"
6:30 pm - 6:40 pmDiscussion
6:40 pm - 7:10 pmMariana Pinho (Instituto de Tecnologia Quimica e Biologica, Portugal)
"Studying Antibiotic Mechanisms of Action at the Single Cell Level"
7:10 pm - 7:20 pmDiscussion
7:20 pm - 7:50 pmJoe Pogliano (University of California, San Diego, USA)
"Bacterial Cytological Profiling: A New Platform for Antibiotic Discovery"
7:50 pm - 8:00 pmDiscussion
8:00 pmDinner
Tuesday
7:30 am - 8:30 amBreakfast
8:30 amGroup Photo
9:00 am - 12:30 pmIdentifying High-Value Chemical Starting Points: Hit Finding Revisited
This session will focus on what defines a high value chemical starting point and where do those come from. Speakers will offer detailed examples to demonstrate how these have enabled/will enable antibacterial drug discovery.
Discussion Leader: Michael Barbachyn (Calvin College, USA)
9:00 am - 9:05 amIntroduction by Discussion Leader
9:05 am - 9:35 amFolkert Reck (Novartis Institutes for Biomedical Research, USA)
"Chemical Property Space – Considerations for Antibacterial Drug Discovery"
9:35 am - 9:45 amDiscussion
9:45 am - 10:15 amChristina Spry (The Australian National University, Australia)
"Fragment-Based Approaches to Antibacterial Lead Discovery: Targeting Coenzyme A Biosynthesis in Mycobacterium tuberculosis"
10:15 am - 10:25 amDiscussion
10:25 am - 10:55 amCoffee Break
10:55 am - 11:25 amOlga Genilloud (Fundación MEDINA, Spain)
"Discovering High Value Hits from Microbial Natural Products"
11:25 am - 11:35 amDiscussion
11:35 am - 12:05 pmMatthew Cooper (The University of Queensland, Australia)
"Chemical Diversity in Screening Libraries for Antibiotic Action: Academic Collections vs. Commercial Libraries"
12:05 pm - 12:15 pmDiscussion
12:15 pm - 12:25 pmBradley Poulsen (Massachussetts General Hospital / Broad Institute, Harvard Medical School, USA)
"A Multiplexed Chemical Screen of Pseudomonas aeruginosa Hypomorphs Rapidly Identifies Novel Antibiotic Leads"
12:25 pm - 12:30 pmDiscussion
12:30 pmLunch
1:30 pm - 4:30 pmFree Time
4:30 pm - 6:00 pmPoster Session
6:00 pm - 8:00 pmAddressing the Gap Between In Vitro (Target) and In Vivo (Cellular) Potency: Strategies to Enable the Latter
This session will focus on strategies to narrow the gap between target and cellular potency, which is a particular challenge in certain types of bacteria such as Gram negatives and TB.
Discussion Leader: Charles Dean (Novartis Intitutes for Biomedical Research, USA)
6:00 pm - 6:05 pmIntroduction by Discussion Leader
6:05 pm - 6:35 pmAthanasios Typas (European Molecular Biology Laboratory, Germany)
"Combinatorial Drug Treatments: From Drug Repurposing to Discovering General Design Principles and Underlying Mechanisms"
6:35 pm - 6:45 pmDiscussion
6:45 pm - 7:10 pmPaolo Ruggerone (University of Cagliari, Italy)
"Membrane Barrier in Drug Resistance: Microscopic Insights into Influx and Efflux Combinations"
7:10 pm - 7:20 pmDiscussion
7:20 pm - 7:50 pmOlga Lomovskaya (The Medicines Company, USA)
"Discovery of Novel Broad-Spectrum Carbapenemase Inhibitors: Challenges and Opportunities"
7:50 pm - 8:00 pmDiscussion
8:00 pmDinner
Wednesday
7:30 am - 8:30 amBreakfast
9:00 am - 12:30 pmLearning from Clinical Experience with Validated Targets
This session will focus on the challenges and opportunities associated with drugs against clinically-precedented antibacterial targets. Examples will provide a learning experience for the community.
Discussion Leader: Michael Dudley (The Medicines Company, USA)
9:00 am - 9:05 amIntroduction by Discussion Leader
9:05 am - 9:40 amSeamus O'Brien (AstraZeneca, United Kingdom)
"Envisioning the Path from Idea to Registration: Lessons from Recent Antibacterial Development Programs"
9:40 am - 9:50 amDiscussion
9:50 am - 10:25 amMary Motyl (Merck Sharp & Dohme Corp., USA)
"Learnings from Planning a Phase 3 Trial of Imipenem/Relebactam Against Imipenem-Resistant Gram Negative Rods"
10:25 am - 10:35 amDiscussion
10:35 am - 11:05 amCoffee Break
11:05 am - 11:40 amJacques Dumas (Tetraphase Pharmaceuticals, Inc., USA)
"Learnings from Planning Global Trials with Eravacycline"
11:40 am - 11:50 amDiscussion
11:50 am - 12:20 pmDaniel Ritz (Actelion Pharmaceuticals Ltd, Switzerland)
"Unique Aspects of Cadezolid, a Novel Quinolonyl-Oxazolidinone in Development for Treatment of C. difficile Infections"
12:20 pm - 12:30 pmDiscussion
12:30 pmLunch
1:30 pm - 4:30 pmFree Time
4:30 pm - 6:00 pmPoster Session
6:00 pm - 8:00 pmLearning from Clinical Experience with Novel Targets
This session will focus on the challenges and opportunities associated with drugs against clinically-unprecedented antibacterial targets. Examples will provide a learning experience for the community.
Discussion Leader: Ursula Theuretzbacher (Center for Anti-Infective Agents, Austria)
6:00 pm - 6:05 pmIntroduction by Discussion Leader
6:05 pm - 6:35 pmAntonio DiGiandomenico (MedImmune, LLC, USA)
"MEDI3902: A Novel Multi-Mechanistic Bispecific Antibody for Prevention of Pneumonia in Ventilated Patients Caused by Pseudomonas aeruginosa"
6:35 pm - 6:45 pmDiscussion
6:45 pm - 7:10 pmFrederick Wittke (Debiopharm International SA, Switzerland)
"Debi0 1450: A New Antimicrobial Agent Specifically Targeting Complicated Staphylococcal Infections"
7:10 pm - 7:20 pmDiscussion
7:20 pm - 7:50 pmRoger Echols (Shionogi Inc., USA)
"Stumbling Towards Approval of a Pathogen-Focused Antibiotic: The Story of S-649266, a Siderophore Cephalosporin"
7:50 pm - 8:00 pmDiscussion
8:00 pmDinner
Thursday
7:30 am - 8:30 amBreakfast
8:30 am - 9:00 amBusiness Meeting
Nominations for the Next Vice Chair; Fill in Conference Evaluation Forms; Discuss Future Site and Scheduling Preferences; Election of the Next Vice Chair
9:00 am - 12:30 pmAlternative Mechanisms of Action and Antibacterial Modalities
This session will focus on non-traditional approaches to antibacterial drugs, including novel combination approaches.
Discussion Leader: Robert Hancock (University of British Columbia, Canada)
9:00 am - 9:05 amIntroduction by Discussion Leader
9:05 am - 9:40 amMan-Wah Tan (Genentech Inc, USA)
"Antibody-Antibiotic Conjugate for Treatment of Bacterial Infections"
9:40 am - 9:50 amDiscussion
9:50 am - 10:25 amCristina Landeta (Harvard Medical School, USA)
"Targeting Disulfide Bond Formation in Bacteria"
10:25 am - 10:35 amDiscussion
10:35 am - 11:00 amCoffee Break
11:00 am - 11:35 amAileen Rubio (Spero Therapeutics, USA)
"Disarming P. aeruginosa Through Inhibition of MvfR"
11:35 am - 11:45 amDiscussion
11:45 am - 11:55 amSelected from Poster Abstracts: Mark Broenstrup (Helmholtz Centre for Infection Research, Germany)
"Induction and Quantification of Small Molecule Uptake into Gram-Negative Bacteria"
11:55 am - 12:00 pmDiscussion
12:00 pm - 12:10 pmSelected from Poster Abstracts: Renee Bouley (University of Notre Dame, USA)
"Exploration of the Mechanism of Action and Structure-Activity Relationship for a New Class of Quinazolinone Antibiotics"
12:10 pm - 12:15 pmDiscussion
12:15 pm - 12:30 pmPoster Previews
12:30 pmLunch
1:30 pm - 4:30 pmFree Time
4:30 pm - 6:00 pmPoster Session
6:00 pm - 8:00 pmThe Future of Antibacterial Diagnostics: How Will New Diagnostics Enable Clinical Trial Design and Clinical Use of New Antibacterials?
Discussion Leader: Herman Goossens (University Hospital Antwerp, Belgium)
6:00 pm - 6:05 pmIntroduction by Discussion Leader
6:05 pm - 6:35 pmLinda Miller (GlaxoSmithKline, USA)
"Precision Medicine and Diagnostics: Trade-Offs, Challenges, and Opportunities"
6:35 pm - 6:45 pmDiscussion
6:45 pm - 7:10 pmDavid Ecker (Ibis Biosciences (Abbott), USA)
"Solutions to Enrolling the Right Patients: Portable Diagnostics"
7:10 pm - 7:20 pmDiscussion
7:20 pm - 7:50 pmDebra Goff (Ohio State University Wexner Medical Center, USA)
"From the Frontline: How Clinicians Apply New Diagnostics Tests"
7:50 pm - 8:00 pmDiscussion
8:00 pmDinner
Friday
7:30 am - 8:30 amBreakfast
9:00 amDeparture

Funding for this conference was made possible [in part] by 1 R13 AI 122053 - 01 from the National Institute of Allergy and Infectious Diseases. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
© 2017 Gordon Research Conferences Search | Contact | Terms of Use | Privacy Policy | Follow us: Facebook Twitter